Newron Pharmaceuticals SpA (NWRN) - Total Assets
Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) holds total assets worth CHF61.39 Million CHF (≈ $77.62 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Newron Pharmaceuticals SpA book value and equity for net asset value and shareholders' equity analysis.
Newron Pharmaceuticals SpA - Total Assets Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals SpA's total assets have evolved over time, based on quarterly financial data.
Newron Pharmaceuticals SpA - Asset Composition Analysis
Current Asset Composition (December 2024)
Newron Pharmaceuticals SpA's total assets of CHF61.39 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 10.9% |
| Accounts Receivable | CHF42.42 Million | 66.4% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF834.00K | 1.3% |
| Intangible Assets | CHF0.00 | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals SpA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NWRN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Newron Pharmaceuticals SpA's current assets represent 95.6% of total assets in 2024, an increase from 90.6% in 2005.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2024, down from 74.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 66.4% of total assets.
Newron Pharmaceuticals SpA Competitors by Total Assets
Key competitors of Newron Pharmaceuticals SpA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Newron Pharmaceuticals SpA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 3.73 | 9.39 |
| Quick Ratio | 1.51 | 3.28 | 9.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF20.39 Million | CHF14.70 Million | CHF38.92 Million |
Newron Pharmaceuticals SpA - Advanced Valuation Insights
This section examines the relationship between Newron Pharmaceuticals SpA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 268.95 |
| Latest Market Cap to Assets Ratio | 5.65 |
| Asset Growth Rate (YoY) | 147.1% |
| Total Assets | CHF63.91 Million |
| Market Capitalization | $360.88 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Newron Pharmaceuticals SpA's assets at a significant premium (5.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Newron Pharmaceuticals SpA's assets grew by 147.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Newron Pharmaceuticals SpA (2005–2024)
The table below shows the annual total assets of Newron Pharmaceuticals SpA from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF63.91 Million ≈ $80.80 Million |
+147.07% |
| 2023-12-31 | CHF25.87 Million ≈ $32.70 Million |
-30.46% |
| 2022-12-31 | CHF37.20 Million ≈ $47.02 Million |
-26.33% |
| 2021-12-31 | CHF50.49 Million ≈ $63.83 Million |
-1.39% |
| 2020-12-31 | CHF51.20 Million ≈ $64.73 Million |
-15.08% |
| 2019-12-31 | CHF60.29 Million ≈ $76.22 Million |
+0.48% |
| 2018-12-31 | CHF60.00 Million ≈ $75.85 Million |
-17.84% |
| 2017-12-31 | CHF73.02 Million ≈ $92.32 Million |
+29.04% |
| 2016-12-31 | CHF56.59 Million ≈ $71.55 Million |
+27.51% |
| 2015-12-31 | CHF44.38 Million ≈ $56.11 Million |
+19.71% |
| 2014-12-31 | CHF37.07 Million ≈ $46.87 Million |
+17.26% |
| 2013-12-31 | CHF31.62 Million ≈ $39.97 Million |
-29.18% |
| 2012-12-31 | CHF44.65 Million ≈ $56.45 Million |
+229.11% |
| 2011-12-31 | CHF13.57 Million ≈ $17.15 Million |
-29.09% |
| 2010-12-31 | CHF19.13 Million ≈ $24.19 Million |
-54.10% |
| 2009-12-31 | CHF41.68 Million ≈ $52.69 Million |
-31.16% |
| 2008-12-31 | CHF60.54 Million ≈ $76.54 Million |
-13.97% |
| 2007-12-31 | CHF70.37 Million ≈ $88.96 Million |
-18.33% |
| 2006-12-31 | CHF86.16 Million ≈ $108.93 Million |
+266.67% |
| 2005-12-31 | CHF23.50 Million ≈ $29.71 Million |
-- |
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more